Diagnosis and treatment of HCV heart diseases

References

• Matsumori A, Matoba Y, Sasayama S. Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation. 1995;92(9):2519–2525.
   PubMed Web of Science ®Google Scholar
• Matsumori A, Yutani C, Ikeda Y, et al. Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy. Laboratory Investigation. 2000;80(7):1137–1142. .
   PubMed Web of Science ®Google Scholar
• Matsumori A. Hepatitis C virus and cardiomyopathy. Circ Res. 2005;9:144–147.
   Google Scholar
• Omura T, Yoshiyama M, Hayashi T, et al. Core protein of hepatitis C virus induces cardiomyopathy. Circ Res. 2005;96:148–150.
   PubMed Web of Science ®Google Scholar
• Pozzi M, Redaelli E, Ratti L, et al. Time course diastolic dysfunction in different stages of chronic HCV related liver diseases. Minerva Gastroenterol Dietol. 2005.
   PubMedGoogle Scholar
• Rombola F, Spinoso A, Bertuccio SN. Cardiac manifestations during viral acute hepatitis. Infez Med. 2006;14:29–32.
   PubMedGoogle Scholar
• Bertuccio SN, Rombolà F, Bertuccio A, et al. HCV infection and pericarditis: an extrahepatic manifestation? Infez Med. 2005;1:42–44.
   Google Scholar
• Matsumori A Cardiovascular effects of HCV. Scientific day in research institute of ophthalmology. December 4,2007 ; Cairo, Egypt.
   Google Scholar
• Nordin C, Kohli A, Beca S, et al. Importance of hepatitis C co-infection in the development of QT prolongation in HIV-infected patients. J Electrocardiol. 2006;39:199–205.
   PubMed Web of Science ®Google Scholar
• Chimenti C, Calabrese F, Thiene G, et al. Inflammatory left ventricular microaneurysms as a cause of apparently idiopathic ventricular tachyarrhythmias. Circulation. 2001;104(2):168–173. .
   PubMed Web of Science ®Google Scholar
• Shichi D, Kikkawa EF, Ota M, et al., The haplotype block, NFKBIL1-ATP6V1G2-BAT1-MICB-MICA, within the class III-class I boundary region of the human major histocompatibility complex may control susceptibility to hepatitis C virus-associated dilated cardiomyopathy. Tissue Antigens. 66(3): 200–208. 2005.
   PubMedGoogle Scholar
• Ishizaka N, Ishizaka Y, Takahashi E, et al., Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet (London, England). 359(9301): 133–135. 2002.
   PubMed Web of Science ®Google Scholar
• Navarro-Gonzalez JF, Mora-Fernandez C, De Fuentes MM, et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nature Rev Nephrol. 2011;7(6):327–340. .
   PubMed Web of Science ®Google Scholar
• Matsumori A, Shimada T, Shimada M, et al. Immunoglobulin free light chains: an inflammatory biomarker of diabetes. Inflamm Res. 2020;69:715–718.
   PubMed Web of Science ®Google Scholar
• Drazilova S, Gazda J, Janicko M, et al. Chronic hepatitis C association with diabetes mellitusand cardiovascular risk in the era of DAA therapy. Can J Gastroenterol Hepatol. 2018;2018:6150861.
   PubMed Web of Science ®Google Scholar
• Huang YW, Yang SS, Fu SC, et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: a nationwide cohort study. Hepatology. 2014;60(3):807–814. .
   PubMed Web of Science ®Google Scholar
• Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126(3):840–848. .
   PubMed Web of Science ®Google Scholar
• Vanni E, Abate ML, Gentilcore E, et al. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology. 2009;50(3):697–706. .
   PubMed Web of Science ®Google Scholar
• Sheikh MY, Choi J, Qadri I, et al. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology. 2008;47(6):2127–2133. .
   PubMed Web of Science ®Google Scholar
• Bastard J-P, Maachi M, Van Nhieu JT, et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab. 2002;87(5):2084–2089. .
   PubMed Web of Science ®Google Scholar
• Nelson DR, Lim HL, Marousis CG, et al. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci. 1997;42:2487–2494.
   PubMed Web of Science ®Google Scholar
• Lecube A, Hernández C, Genescà J, et al. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study. Diabetes Care. 2006;29:1096–1110.
   PubMed Web of Science ®Google Scholar
• Mirza MS. Obesity, visceral fat, and NAFLD: querying the role of adipokines in the progression of nonalcoholic fatty liver disease. ISRN Gastroenterol. 2011;2011:592404.
   PubMedGoogle Scholar
• Tang W, Xu Q, Hong T, et al. Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. Diabetes Metab Res Rev. 2016;32:200–216.
   PubMed Web of Science ®Google Scholar
• Calzadilla-Bertot L, Vilar-Gomez E, Torres- Gonzalez A, et al. Impaired glucose metabolism increases risk of hepatic decompensation and death in patients with compensated hepatitis C virus-related cirrhosis. Dig Liver Dis. 2016;48:283–290.
   PubMedGoogle Scholar
• Lonardo A, Adinolfi LE, Petta S, et al. Hepatitis C and diabetes: the inevitable coincidence? Expert Rev Anti Infect Ther. 2009;7:293–308.
   PubMed Web of Science ®Google Scholar
• Babiker A, Jeudy J, Kligerman S, et al. Risk of cardiovascular disease due to chronic hepatitis c infection: a review. J Clin Transl Hepatol. 2017;5:343–362.
   PubMed Web of Science ®Google Scholar
• Targher G, Bertolini L, Padovani R, et al. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol. 2007;46:1126–1132.
   PubMed Web of Science ®Google Scholar
• Mostafa A, Mohamed MK, Saeed M, et al. Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut 2010;59:1135–1140.
   PubMed Web of Science ®Google Scholar
• Boddi M, Abbate R, Chellini B, et al. Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol. 2010;47:72–75.
   PubMed Web of Science ®Google Scholar
• Adinolfi LE, Rinaldi L, Nevola R. Chronic hepatitis C, atherosclerosis and　 cardiovascular disease: what impact of direct-acting antiviral treatments? World J Gastroenterol. 2018;24:4617–4621.
   PubMed Web of Science ®Google Scholar
• Petta S, Adinolfi LE, Fracanzani AL, et al. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. J Hepatol. 2018;69:18–24.
   PubMed Web of Science ®Google Scholar
• Vassalle C, Maisini S, Bianchi F, et al. Evidence of association between hepatitis C virus seropositivity and coronary artery disease. Heart. 2004;90:565–566.
   PubMed Web of Science ®Google Scholar
• Haji SA, Starling RC, Avery RK, et al. Donor hepatitis C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. J Heart Lung Transplant. 2004;23:277–283.
   PubMed Web of Science ®Google Scholar
• Marelli D, Bresson J, Laks H, et al. Hepatitis C-positive donors in heart transplantation. Am J Transplant. 2002;2:443–447, Heart Transplant Program, University of California, Los Angeles, USA
   PubMed Web of Science ®Google Scholar
• Peng Q, Wei Z. Lau BHS Pycnogenol inhibits tumor necrosis factor-α-induced nuclear factor kappa B activation and adhesion molecule expression in human vascular endothelial cells. Cell Mol Life Sci. 2000;57:834–841.
   PubMed Web of Science ®Google Scholar
• Cho KJ, Yun CH, Yoon DY, et al. Effect of bioflavonoids extracted from the bark of Pinus maritime on proinflammatory cytokine interleukin-1 production in lipopolysaccharide-stimulated RAW 2647. Toxicol Appl Pharmacol. 2000;168:64–71.
   PubMed Web of Science ®Google Scholar
• Bayeta E. Pycnogenol inhibits release of reactive oxygen species and NO from macrophages. Nutr Res. 2000;20:249–259.
   Web of Science ®Google Scholar
• Ezzikouri S, Nishimura T, Kohara M, et al. Inhibitory effects of Pycnogenol on hepatitis C virus replication. Antiviral Res. 2015;113:93–102.
   PubMed Web of Science ®Google Scholar
• Hiramatsu SH, Maruyama T, Ito H, et al. Influence of Interferon Therapy on signal-averaged and ambulatory electrocardiograms in patients with chronic active hepatitis. Int Heart J. 2005;46:1033–1040.
   PubMed Web of Science ®Google Scholar
• Frustaci A, Calabrese F, Chimenti C, et al. Lone hepatitis C virus myocarditis responsive to immunosuppressive therapy. Chest. 2002;122:1348–1356.
   PubMed Web of Science ®Google Scholar
• Matsumori A, Shimada M, Obata T. Leukocytes are the major target of hepatitis C virus infection: possible mechanism of multiorgan involvement including the heart. CVD Prevention and Control. 2010;5:51–58.
   Google Scholar
• Matsumori A, Otani M, Otani H, et al. Hepatirtis C virus infection as a cause of cardiomyopathies and nephritis. (abstract). Presented at International Congress of Cardiomyopathies and Heart failure, 2016, Kyoto, Japan.
   Google Scholar
• Fueda Y, Kotera H, Matsumori A. Prevention of nutritional deficiencies in chronic hepatitis C patients. New virus removal treatment. ESPEN 2019. ESPEN19-LB–2137.
   Google Scholar
• Haykal M, Negm H, Negm E, et al. Assessment of myocardial functions in Egyptian patients with hepatits C viral infection. Master thesis 2008; 111–112
   Google Scholar
• Haykal M Assessment of left atrial functions in HCV patients with and without cardiovascular risk factors. Poster presentation. Cardioalex conference 2010.
   Google Scholar
• Saleh A, Matsumori A, Negm H, et al. Assessment of cardiac involvement of hepatitis C virus; tissue Doppler imaging and NT pro BNP study. J Saudi Heart Assoc. 2011;23:217–223.
   PubMedGoogle Scholar
• Haykal M, Matsumori A, Negm H. Anti-inflammatory treatment with cetirizine improves refractory heart failure in patients with hepatitis C virus- induced myocarditis. Can J Cardiol. 2014;30(10):S121.
   Google Scholar